Dermatological compounds

Details Dermatological compounds Dermatological compounds

1998-05-28

2001-04-10

Reamer, James H. (Department: 1614)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

C-o-group doai

C568S819000, C568S820000

Reexamination Certificate

active

06214888

ABSTRACT:

BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to novel monocyclic and bicyclic monoterpene diols that stimulate melanogenesis in mammalian skin, hair, wool or fur, and, are useful for treating or preventing various skin and proliferative disorders, neurodegenerative diseases, and diseases regulated by the nitric oxide/cyclic GMP/protein kinase G pathway.
2. Description of Related Art
U.S. Pat. No. 5,352,440 is directed to increasing melanin synthesis in melanocytes and increasing pigmentation by administration of certain diacylglycerol compounds.
U.S. Pat. No. 5,532,001 is directed to increasing pigmentation in mammalian skin via administration of certain DNA fragments.
U.S. Pat. No. 5,554,359 is directed to increasing levels of melanin in melanocytes by administration of lysosomotropic agents.
SUMMARY OF THE INVENTION
In one aspect, the present invention is directed to compounds having the structure:
wherein
A is a substituted or unsubstituted cyclic terpene;
R
1
, R
2
, R
8
and R
9
are all —OH; and
R
3
, R
4
, R
5
, R
6
, R
7
and R
10
are each independently hydrogen, or a linear or branched, cyclic, bicyclic or polycyclic group containing from one atom to fifty atoms, at least one of which is carbon, nitrogen, oxygen, or sulfur.
Another aspect of the present invention concerns stimulation of melanogenesis in mammalian skin, hair, wool or fur, by administering to a locus in need of such stimulation an effective amount of one or more of the compounds described above.
Another aspect of the present invention concerns treatment of proliferative, tumorous or cancerous disorders in mammals, including but not limited to such conditions of a dermatological nature, by administering to a mammal in need of such treatment an effective amount of one or more of the compounds described above.
A further aspect of the present invention concerns treatment of neurodegenerative disorders or nerve damage in mammals by administering to a mammal in need of such treatment an effective amount of one or more of the compounds described above.
Another aspect of the present invention concerns treatment of diseases regulated by the nitric oxide/cyclic GMP/protein kinase G pathway in mammals by administering to a mammal in need of such treatment an effective amount of one or more of the compounds described above.


REFERENCES:
patent: 3956361 (1976-05-01), Stephen
patent: 4104203 (1978-08-01), Hall et al.
patent: 4626603 (1986-12-01), Siegmeier et al.
patent: 4647585 (1987-03-01), Loots et al.
patent: 5068453 (1991-11-01), Kuwahara et al.
patent: 5130136 (1992-07-01), Shono et al.
patent: 5352440 (1994-10-01), Gilchrest et al.
patent: 5414019 (1995-05-01), Gould et al.
patent: 5532001 (1996-07-01), Gilchrest et al.
patent: 5554359 (1996-09-01), Fuller
patent: 5574195 (1996-11-01), Chastain et al.
patent: 5587402 (1996-12-01), Gould et al.
patent: 5591423 (1997-01-01), Fuller
patent: 5602184 (1997-02-01), Myers et al.
patent: 5645839 (1997-07-01), Chobanian et al.
patent: 5698184 (1997-12-01), Pickart
patent: 5700450 (1997-12-01), Gilchrest et al.
patent: 5747532 (1998-05-01), Lai
patent: 5837738 (1998-11-01), Williamson et al.
patent: 5990177 (1999-11-01), Brown
patent: 1 200 862 (1970-08-01), None
patent: WO96/26711 (1996-09-01), None
patent: WO 98/11882 (1998-03-01), None
Merket et al, Chem. Abstracts, vol. 66, #94723a, 1967.*
Ishida et al, Chem. Abstracts, vol. 93, #89860w, 1980.*
Buchbauer et al, Chem. Abstracts, vol. 95, #115756e, 1981.*
Uchida et al, Chem. Abstracts, VGol. 112, #198816t, 1990.*
Kozlov et al, Chem. Abstracts, vol. 120, #77469p, 1994.*
Miftakhov et al, Chem. Abstracts, vol. 121, #157329d, 1994.*
Kemikubo et al, Chem. Abstracts, vol. 122, #265669u, 1995.*
Koval'skaya et al., Chem. Abstracts, vol. 125, #276201y. 1996.*
Adnot et al., “Pulmonary hypertension: NO therapy?,”Thorax,1996, 51:762-764.
Andersson and Stief, “Neurotransmission and the contraction and relaxation of penile erectile tissues,” 1997,World J. Urol.15:14-20 (abstract).
Andersson, K.-E., “Neurotransmitters and neuroreceptors in the lower urinary tract,”Curr. Opin. Obstet Gynecol.,1996, 8:361-365.
Baron, A., “Insulin and the Vasculature—Old Actors, New Roles,”J. Investig. Med.,1996, 44:406-412.
Barry, B. W. “Properties that Influence Percutaneous Absorption,”Dermatological Formulations: Percutaneous Absorption,Marcel Dekker, Inc., New York, ,1983, pp. 127-233.
Barthelman et al., “Inhibitory Effects of Perillyl Alcohol on UVB-induced Murine Skin Cancer and AP-1 Transactivation,”Cancer Research,Feb. 15, 1998, 58:711-716.
Baudouin et al., “Constitutive Nitric Oxide Synthase is Present in Normal Human Keratinocytes,”J. Invest. Dermatol.,1996, 106:428-431.
Brann et al., “Gaseous Transmitters and Neuroendocrine Regulation,”Neuroendocrinology,1997, 65:385-395.
Brown et al., “Aliphatic and Alicyclic Diols Induce Melanogenesis in Cultured Cells and Guinea Pig Skin,”J. Invest. Dermatol.,1998, 110:428-437.
Buchbauer et al., “Norbornanaverbindungen in der pharmazeutischen Forschung,”Pharmazie,1991, 46(Teil 1):88-97, and 46(Teil 2):116-170.
Carter et al., “Nitric oxide production is intensely and persistently increased in tissue by thermal injury,”Biochem. J.,1994, 304(Pt 1):201-04.
Cooke et al., “Nitric Oxide Synthase: Role in the Genesis of Vascular Disease,”Annu. Rev. Med.,1997, 48:489-509.
Crowell et al., “Chemoprevention of mammary carcinogenesis by hydroxylated derivatives of d-limonene,”Carcinogenesis,1992, 13:1261-1264.
Crowell et al., “Structure-activity relationships among monoterpene inhibitors of protein isoprenylation and cell proliferation,”Biochemical Pharmacology,1994, 47:1405-1415.
Dawson et al., “Nitric Oxide Actions in Neurochemistry,”Neurochem. Int.,1996, 29:97-110.
Gorfine, S., “Treatment of Benign Anal Disease with Topical Nitroglycerin,”Dis. Colon Rectum,1995, 38:453-456.
Haag et al., “Mammary carcinoma regression induced by perillyl alcohol, a hydroxilated analog of limonene,”Cancer Chemotherapy and Pharmacology,1994, 34:477-483.
He et al., “Isoprenoids Suppress the Growth of Murine B16 Melanomas In Vitro and In Vivo,”J. Nutr.,1997, 127:668-674.
Hidaka et al., “Isoquinolinesulfonamides, Novel and Potent Inhibitors of Cyclic Nucleotide Dependent Protein Kinase and Protein Kinase C,”Biochemistry,1984, 23, 5036-5041.
Jager et al., “Investigation of cytotoxic effects of 8 norbornane derivatives on 4 human cancer cell lines using the MTT assay,”Pharmazie,1995, 50:619-621.
Karlberg et al., “Hydroperoxides in oxidizedd-limonene identified as potent contact allergens,”Arch. Dermatol. Res.,1994, 286:97-103.
Kitahara et al., “Evaluation of Skin Damage of Cyclic Monoterpenes, Percutaneous Absorption Enhancers, by Using Cultured Human Skin Cells,”Biol. Pharm. Bull.,1993, 16:912-916.
Kone, et al., “Biosynthesis and homeostatic roles of nitric oxide in the normal kidney,”Am. J. Physiol.,1997, 10:F561-578.
Lahera et al., “Nitric Oxide, the Kidney and Hypertension,”Am. J. Hypertens.,1997, 10:129-140.
Marriott and Higenbottam, “The role of nitric oxide in respiratory disease,” 1997,Schweiz Med. Wochenschr.127:709-714 (abstract).
Mashimo et al., “Effects of Vasodilators Guanethidine, Nicardipine, Nitroglycerin, and Prostaglandin E1on Primary Afferent Nociceptors in Humans,”J. Clin. Pharmacol.,1997, 37:330-335.
Miles et al., “Fluorometric Determination of Nitric Oxide,”Methods,1995, 7:40-47.
Murrell et al., “Modulation of tendon healing by nitric oxide,”Inflamm. Res.,1997, 46:19-27.
Ohmori et al., “Pharmacological Regulation on Melanogenesis,”Nippon Koshohin Kagakkaishi,1994, 18:215-219. English translation attached1.
Packard et al., “Pathogenesis of Posttraumatic Headache and Migraine: A Common Headache Pathway?”Headache,1997, Mar. 37:142-152.
Pipili-Synetos et al., “Inhibition of angiogenesis, tumor growth and metastasis by the NO-releasing vasodilators, isosorbide mononitrate and dinitrate,”Br. J. Pharmacol.,1995, 116:1829-1834.
Rishi et al., “Gastrointestinal Protection by NO from NSAIDS Induced Injury,”Indian J. Physiol. Pharmacol.,19

Affiliated with

Also associated with

Rating

Dermatological compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Dermatological compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Dermatological compounds will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2457073